WO2023030299A1 - 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途 - Google Patents

一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途 Download PDF

Info

Publication number
WO2023030299A1
WO2023030299A1 PCT/CN2022/115763 CN2022115763W WO2023030299A1 WO 2023030299 A1 WO2023030299 A1 WO 2023030299A1 CN 2022115763 W CN2022115763 W CN 2022115763W WO 2023030299 A1 WO2023030299 A1 WO 2023030299A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell lymphoma
day
peripheral
dosage
formula
Prior art date
Application number
PCT/CN2022/115763
Other languages
English (en)
French (fr)
Inventor
张晓静
王维伟
Original Assignee
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to KR1020247010785A priority Critical patent/KR20240056564A/ko
Priority to PE2024000331A priority patent/PE20240881A1/es
Priority to CA3230149A priority patent/CA3230149A1/en
Priority to AU2022340500A priority patent/AU2022340500A1/en
Priority to IL311097A priority patent/IL311097A/en
Priority to CN202280058583.6A priority patent/CN117956995A/zh
Priority to EP22863434.1A priority patent/EP4393490A1/en
Publication of WO2023030299A1 publication Critical patent/WO2023030299A1/zh
Priority to CONC2024/0003923A priority patent/CO2024003923A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the disclosure relates to the use of an EZH2 inhibitor for preparing a drug for treating T-cell lymphoma, and belongs to the field of medicine.
  • EZH2 is the core component of histone methyltransferase PRC2 (polycombrepressive complex 2), which is triggered by catalyzing the trimethylation of the 27th lysine at the amino terminal of histone H3 (H3K27Me3) And maintain the transcriptional repression state of chromosomes, inhibit the expression of target genes.
  • Most of these target genes have the functions of inhibiting cell proliferation and promoting cell differentiation, thus playing an important role in the process of maintaining embryonic development and resisting cell aging.
  • Peripheral T-cell lymphoma also known as mature T-cell lymphoma, is a group of malignant proliferative diseases with obvious heterogeneity originating from mature T lymphocytes. Because the immune manifestations and functions of NK cells are similar to those of T cells , Therefore, NK cell lymphoma and mature T cell lymphoma are often classified into one category.
  • HDAC Histone deacetylase
  • folic acid inhibitors have been approved for such patients, but the curative effect is limited.
  • more new and effective drugs still need to be developed and marketed to improve the prognosis of patients with relapsed and refractory PTCL.
  • the present disclosure provides the use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating T-cell lymphoma,
  • the T cell lymphoma of the present disclosure is a peripheral T cell lymphoma (mature T and NK cell lymphoma).
  • the T-cell lymphoma of the present disclosure is angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma-not specified (PTCL- NOS) or NK/T-cell lymphoma (NKTCL).
  • AITL angioimmunoblastic T-cell lymphoma
  • ALCL anaplastic large cell lymphoma
  • PTCL- NOS peripheral T-cell lymphoma-not specified
  • NKTCL NK/T-cell lymphoma
  • the T-cell lymphoma of the present disclosure is angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma-not specified.
  • the T-cell lymphoma of the present disclosure is angioimmunoblastic T-cell lymphoma.
  • the T-cell lymphoma of the present disclosure is peripheral T-lymphoma-not specified.
  • the T-cell lymphoma of the present disclosure is relapsed/refractory peripheral T-cell lymphoma.
  • the T-cell lymphoma of the present disclosure is peripheral T-cell lymphoma that has received first-line chemotherapy.
  • the T-cell lymphoma of the present disclosure is a peripheral T-cell lymphoma that has received at least one treatment selected from histone deacetylase inhibitors, folic acid metabolism inhibitors, or anti-CD30 monoclonal antibodies.
  • the T-cell lymphoma described in the present disclosure is a peripheral T-cell lymphoma treated with first-line chemotherapy and at least one selected from histone deacetylase inhibitors, folic acid metabolism inhibitors, or anti-CD30 monoclonal antibodies. tumor.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from 1 mg to 800 mg, and the frequency of administration is once a day or twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from 2.5 mg, 5.0 mg, 7.5 mg, 10.0 mg, 12.5 mg, 15.0 mg, 17.5 mg, 20.0 mg, 22.5mg, 25.0mg, 27.5mg, 30.0mg, 32.5mg, 35.0mg, 37.5mg, 40.0mg, 42.5mg, 45.0mg, 47.5mg, 50.0mg, 52.5mg, 55.0mg, 57.5mg, 60.0mg, 62.5mg , 65.0mg, 67.5mg, 70.0mg, 72.5mg, 75.0mg, 77.5mg, 80.0mg, 82.5mg, 85.0mg, 87.5mg, 90.0mg, 92.5mg, 95.0mg, 97.5mg, 100.0mg, 105.0 mg, 107.5mg, 110.0mg, 112.5mg, 115.0mg, 117.5mg, 120.0
  • the dosage of the compound represented by formula (I) or its pharmaceutically acceptable salt is selected from 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, 300mg, 350mg, 375mg, 400mg, 425mg, 450mg, 475mg, 500mg, 525mg, 550mg, 575mg or 600mg, the administration frequency is once a day or twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from 50 mg, 100 mg, 200 mg, 300 mg, 350 mg or 400 mg, and the frequency of administration is once a day or twice a day .
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from 200 mg, 300 mg or 350 mg, and the dosage is once a day or twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is 200 mg, and the dosage is once or twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is 300 mg, and the frequency of administration is once a day or twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is 350 mg, and the frequency of administration is once a day or twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from 200 mg, 300 mg or 350 mg, and the dosage is twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is 200 mg, and the frequency of administration is twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is 300 mg, and the frequency of administration is twice a day.
  • the dosage of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is 350 mg, and the frequency of administration is twice a day.
  • Another aspect of the present disclosure provides a method for treating T-cell lymphoma, which comprises administering a therapeutically effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof to a patient.
  • Another aspect of the present disclosure provides a method for treating T-cell lymphoma, administering 1 mg-800 mg of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof to the patient, and the frequency of administration is once a day or twice a day Second-rate.
  • 28 days is one administration cycle.
  • Another aspect of the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof for treating T-cell lymphoma.
  • patient as used in this disclosure means a human being.
  • acetylase inhibitors described in the present disclosure include but not limited to chidamide, belistat or romidepsin; the described folic acid metabolism inhibitors include but not limited to pralatrexate; CD30 antibodies, including but not limited to velbutuximab.
  • compositions which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
  • the pharmaceutical composition may be specially formulated for oral administration in solid or liquid form, or for topical administration.
  • the present disclosure further provides the use of a composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers in the preparation of a medicament for treating T-cell lymphoma.
  • the "pharmaceutically acceptable carrier” in the present disclosure means any type of non-toxic inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary material.
  • substances that may serve as pharmaceutically acceptable carriers are sugars such as lactose or cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate.
  • patients in the present disclosure have received first-line chemotherapy and at least one new drug (chidamide, pralatrexate, velbutuximab) treatment, wherein:
  • -NKTCL received treatment with asparaginase/pegaspargase regimen
  • -Other subtypes Previously treated with CHOP or CHOP-like regimens (including but not limited to CHOEP, BV+CHP).
  • relapse is refractory
  • relapse refers to disease progression after remission of the last line of treatment
  • refractory refers to failure to achieve remission after the last treatment.
  • ORR Defined from the first administration to the occurrence of PD or the initiation of subsequent new anti-tumor therapy, whichever occurs first, the proportion of subjects with the best curative effect reaching CR or PR.
  • PFS defined as the date from the start of the first dose to the first documented PD or death from any cause, whichever occurred first. If the subject still has no PD or death on the data cut-off date, the cut-off date is the date of the last efficacy evaluation of the subject. If the subject has not received tumor assessment, the cut-off date is the date of the first dose, and the PFS lasts for 1 day.
  • DoR Defined as the time from first assessment of CR or PR to first assessment of PD or death from any cause, whichever occurs first. If the subject still has no PD or death on the data cut-off date, the cut-off date is the date of the last efficacy evaluation of the subject. Only applicable to subjects who achieved CR or PR.
  • Disease progression was defined as the deterioration of the subject's condition due to the indication of the study. Including imaging progress, test result progress and clinical symptoms and signs progress. The appearance of new lesions or the progression of existing lesions were considered as disease progression. Events that are life-threatening, require hospitalization or prolonged hospitalization, or result in permanent or severe disability/incapacity/impair work capacity, congenital anomalies, or birth defects due to symptoms and signs of disease progression are not reported as SAEs. Deaths due to symptoms and signs of disease progression were reported as SAEs.
  • an “effective amount” or “therapeutically effective amount” as used in the present disclosure includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical condition.
  • An effective amount also means an amount sufficient to permit or facilitate diagnosis.
  • Effective amounts for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the method, route and dosage of administration, and the severity of side effects.
  • An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
  • Embodiment 1 the effectiveness research of the compound shown in formula (I) to peripheral T-cell lymphoma
  • the overall ORR was 50%. Among them, there were 9 cases of PTCL-NOS and 15 cases of AITL. The ORRs of the two groups were 44.4% and 53.3%, respectively. There were 18 cases in the ES group, and the ORR was 66.7%. Among them, there were 7 cases of PTCL-NOS and 11 cases of AITL. The ORRs of the two groups were 57.1% and 72.7%, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及一种EZH2抑制剂用于制备治疗T细胞淋巴瘤的药物的用途。具体而言，涉及一种式(I)所示化合物或其药学上可接受的盐在制备治疗T细胞淋巴瘤的药物中的用途。

Description

一种EZH2抑制剂用于制备治疗T细胞淋巴瘤的药物的用途
本申请要求申请日为2021年8月30日的中国专利申请2021110016631的优先权。本申请引用上述中国专利申请的全文。
技术领域
本公开涉及一种EZH2抑制剂用于制备治疗T细胞淋巴瘤的药物的用途，属于医药领域。
背景技术
EZH2(enhancer of zeste homolog 2)是组蛋白甲基化转移酶PRC2(polycombrepressive complex 2)的核心成分，其通过催化组蛋白H3氨基末端第27位赖氨酸发生三甲基化(H3K27Me3)而触发和维持染色体的转录抑制状态，抑制靶基因表达。这些靶基因大部分具有抑制细胞增殖和促进细胞分化的作用，从而在维持胚胎发育、抗细胞衰老的过程中发挥重要作用。
外周T细胞性淋巴瘤(PTCL)又称成熟T细胞淋巴瘤，是一组起源于成熟T淋巴细胞的具有明显异质性的恶性增殖性疾病，由于NK细胞的免疫表现及功能与T细胞相似，因此常将NK细胞淋巴瘤和成熟T细胞淋巴瘤归为一类。
目前PTCL尚无标准治疗方案，常用一线治疗为CHOP或CHOP样方案、5年生存率仅约30％。对于复发或难治性PTCL(rrPTCL)，国内外推荐首先临床试验，其他I级专家推荐治疗包括新药单药及联合化疗，但传统化疗疗效不理想。国内现有西达本胺、普拉曲沙获批用于rrPTCL的治疗，ORR 27-52％、PFS 2.1-4.8个月。经新药治疗后复发或难治的患者、无可用治疗。 总之，传统化疗在复发难治PTCL的疗效不理想，组蛋白去乙酰化酶(HDAC)抑制剂及叶酸抑制剂获批用于此类患者，但疗效提高有限。目前仍需要研发更多新型、有效的药物上市，以改善复发难治PTCL患者的预后。
发明内容
本公开提供一种式(I)所示化合物或其药学上可接受的盐在制备治疗T细胞淋巴瘤的药物中的用途，
Figure PCTCN2022115763-appb-000001
一些实施方案中，本公开所述的T细胞淋巴瘤为外周T细胞淋巴瘤(成熟T和NK细胞淋巴瘤)。
一些实施方案中，本公开所述的T细胞淋巴瘤为血管免疫母细胞性T细胞淋巴瘤(AITL)、间变性大细胞淋巴瘤(ALCL)、外周T淋巴细胞瘤-非特指型(PTCL-NOS)或NK/T细胞淋巴瘤(NKTCL)。
一些实施方案中，本公开所述的T细胞淋巴瘤为血管免疫母细胞性T细胞淋巴瘤或外周T淋巴细胞瘤-非特指型。
一些实施方案中，本公开所述的T细胞淋巴瘤为血管免疫母细胞性T细胞淋巴瘤。
一些实施方案中，本公开所述的T细胞淋巴瘤为外周T淋巴细胞瘤-非特指型。
一些实施方案中，本公开所述的T细胞淋巴瘤为复发/难治外周T细胞淋巴瘤。
一些实施方案中，本公开所述的T细胞淋巴瘤为接受过一线化疗的外周T细胞淋巴瘤。
一些实施方案中，本公开所述的T细胞淋巴瘤为接受过至少一种选自组蛋白去乙酰化酶抑制剂、叶酸代谢抑制剂、或抗CD30单抗治疗的外周T细胞淋巴瘤。
一些实施方案中，本公开所述的T细胞淋巴瘤为接受过一线化疗和至少一种选自组蛋白去乙酰化酶抑制剂、叶酸代谢抑制剂、或抗CD30单抗治疗的外周T细胞淋巴瘤。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量选自1mg-800mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量选自2.5mg、5.0mg、7.5mg、10.0mg、12.5mg、15.0mg、17.5mg、20.0mg、22.5mg、25.0mg、27.5mg、30.0mg、32.5mg、35.0mg、37.5mg、40.0mg、42.5mg、45.0mg、47.5mg、50.0mg、52.5mg、55.0mg、57.5mg、60.0mg、62.5mg、65.0mg、67.5mg、70.0mg、72.5mg、75.0mg、77.5mg、80.0mg、82.5mg、85.0mg、87.5mg、90.0mg、92.5mg、95.0mg、97.5mg、100.0mg、102.5mg、105.0mg、107.5mg、110.0mg、112.5mg、115.0mg、117.5mg、120.0mg、122.5mg、125.0mg、127.5mg、130.0mg、132.5mg、135.0mg、137.5mg、140.0mg、142.5mg、145.0mg、147.5mg、150.0mg、152.5mg、155.0mg、157.5mg、160.0mg、162.5mg、165.0mg、167.5mg、170.0mg、172.5mg、175.0mg、177.5mg、180.0mg、182.5mg、185.0mg、187.5mg、190.0mg、192.5mg、195.0mg、197.5mg、200.0mg、202.5mg、205.0mg、207.5mg、210.0mg、212.5mg、215.0mg、217.5mg、220.0mg、222.5mg、225.0mg、227.5mg、230.0mg、232.5mg、235.0mg、237.5mg、240.0mg、242.5mg、245.0mg、247.5mg、250.0mg、252.5mg、255.0mg、 257.5mg、260.0mg、262.5mg、265.0mg、267.5mg、270.0mg、272.5mg、275.0mg、277.5mg、280.0mg、282.5mg、285.0mg、287.5mg、290.0mg、292.5mg、295.0mg、297.5mg、300.0mg、302.5mg、305.0mg、307.5mg、310.0mg、312.5mg、315.0mg、317.5mg、320.0mg、322.5mg、325.0mg、327.5mg、330.0mg、332.5mg、335.0mg、337.5mg、340.0mg、342.5mg、345.0mg、347.5mg、350.0mg、352.5mg、355.0mg、357.5mg、360.0mg、362.5mg、365.0mg、367.5mg、370.0mg、372.5mg、375.0mg、377.5mg、380.0mg、382.5mg、385.0mg、387.5mg、390.0mg、392.5mg、395.0mg、397.5mg、400.0mg、402.5mg、405.0mg、407.5mg、410.0mg、412.5mg、415.0mg、417.5mg、420.0mg、422.5mg、425.0mg、427.5mg、430.0mg、432.5mg、435.0mg、437.5mg、440.0mg、442.5mg、445.0mg、447.5mg、450.0mg、452.5mg、455.0mg、457.5mg、460.0mg、462.5mg、465.0mg、467.5mg、470.0mg、472.5mg、475.0mg、477.5mg、480.0mg、482.5mg、485.0mg、487.5mg、490.0mg、492.5mg、495.0mg、497.5mg、500.0mg、502.5mg、505.0mg、507.5mg、510.0mg、512.5mg、515.0mg、517.5mg、520.0mg、522.5mg、525.0mg、527.5mg、530.0mg、532.5mg、535.0mg、537.5mg、540.0mg、542.5mg、545.0mg、547.5mg、550.0mg、552.5mg、555.0mg、557.5mg、560.0mg、562.5mg、565.0mg、567.5mg、570.0mg、572.5mg、575.0mg、577.5mg、580.0mg、582.5mg、585.0mg、587.5mg、590.0mg、592.5mg、595.0mg、597.5mg、600.0mg、602.5mg、605.0mg、607.5mg、610.0mg、612.5mg、615.0mg、617.5mg、620.0mg、622.5mg、625.0mg、627.5mg、630.0mg、632.5mg、635.0mg、637.5mg、640.0mg、642.5mg、645.0mg、647.5mg、650.0mg、652.5mg、655.0mg、657.5mg、660.0mg、662.5mg、665.0mg、667.5mg、670.0mg、672.5mg、675.0mg、677.5mg、680.0mg、682.5mg、685.0mg、687.5mg、690.0mg、692.5mg、 695.0mg、697.5mg、700.0mg、702.5mg、705.0mg、707.5mg、710.0mg、712.5mg、715.0mg、717.5mg、720.0mg、722.5mg、725.0mg、727.5mg、730.0mg、732.5mg、735.0mg、737.5mg、740.0mg、742.5mg、745.0mg、747.5mg、750.0mg、752.5mg、755.0mg、757.5mg、760.0mg、762.5mg、765.0mg、767.5mg、770.0mg、772.5mg、775.0mg、777.5mg、780.0mg、782.5mg、785.0mg、787.5mg、790.0mg、792.5mg、795.0mg、797.5mg或800.0mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量选自50mg、75mg、100mg、125mg、150mg、175mg、200mg、225mg、250mg、275mg、300mg、350mg、375mg、400mg、425mg、450mg、475mg、500mg、525mg、550mg、575mg或600mg，给药频次一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量选自50mg、100mg、200mg、300mg、350mg或400mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量选自200mg、300mg或350mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量为200mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量为300mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量为350mg，给药频次为一日一次或一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量选自200mg、300mg或350mg，给药频次为一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量为200mg，给药频次为一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量为300mg，给药频次为一日两次。
一些实施方案中，式(I)所示化合物或其药学上可接受的盐的给药剂量为350mg，给药频次为一日两次。
本公开另一方面提供一种治疗T细胞淋巴瘤的方法，给与患者治疗有效量的式(I)所示化合物或其药学上可接受的盐。
本公开另一方面提供一种治疗T细胞淋巴瘤的方法，给与患者1mg-800mg的式(I)所示化合物或其药学上可接受的盐，给药频次为一日一次或一日两次。
一些实施方案中，本公开提供的治疗T细胞淋巴瘤的方法，28天为一个给药周期。
本公开另一方面提供一种用于治疗的T细胞淋巴瘤的式(I)所示化合物或其药学上可接受的盐。
本公开中所使用的术语“患者”意指人类。
本公开中所述的乙酰化酶抑制剂包括但不限于西达本胺、贝利司他或罗米地辛；所述的叶酸代谢抑制剂包括但不限于普拉曲沙；所述的抗CD30抗体，包括但不限于维布妥昔单抗。
本公开另一方面提供一种药物组合物，其含有式(I)所示化合物或其药学上可接受的盐与一或多种药学上可接受的载体。该药物组合物可特别被配制成用于口服施用的固体或液体形式，或用于局部施用。
本公开进一步提供一种含有式(I)所示化合物或其药学上可接受的盐与一或多种药学上可接受的载体的组合物在制备治疗T细胞淋巴瘤的药物中的用途。
本公开中所述的“药学上可接受的载体”意指任何类型的无毒的惰性固体、半固体或液体填充剂、稀释剂、包封材料或配制辅料。一些可作为药学上可接受的载体的物质的实例为糖类，例如：乳糖或纤维素及其衍生物，诸如羧甲基纤维素钠、乙基纤维素及醋酸纤维素。
可选的实施方案中，本公开中的患者接受过一线化疗和至少一种新药(西达本胺、普拉曲沙、维布妥昔单抗)治疗，其中：
-CD30系统型ALCL，接受过维布妥昔单抗治疗；
-NKTCL：接受过门冬酰胺酶/培门冬酶方案的治疗；
-其他亚型：接受过CHOP或CHOP样方案(包括但不限于CHOEP、BV+CHP)治疗。
本公开中所述复发难治，复发为末线治疗缓解后出现疾病进展，难治为末次治疗未达到缓解。
ORR：定义自首次给药开始到发生PD或开始后续新的抗肿瘤治疗，以先出现者为准，最佳疗效达到CR或PR的受试者比例。
PFS：定义为从首次给药开始到首次记录PD或任何原因导致死亡的日期，以先出现者为准。如果在数据截止日期受试者仍没有发生PD或死亡，截止日期为受试者最后一次疗效评估的日期。如果受试者未接受肿瘤评估，截止日期为首次服药日期，PFS持续1天。
DoR：定义为从第一次评估为CR或PR开始到第一次评估为PD或任何原因导致死亡的时间，以先出现者为准。如果在数据截止日期受试者仍没有发生PD或死亡，截尾日期为受试者最后一次疗效评估的日期。只适用于取得CR或PR的受试者。
疾病进展定义为研究的适应症引起的受试者情况恶化。包括影像学进展、检验结果进展和临床症状、体征的进展。出现新病灶，或原有病灶的进展均认为是疾病进展。因疾病进展的症状和体征而引起的危及生命，需 要住院治疗或延长住院时间，或导致永久性或严重残疾/功能不全/影响工作能力，先天异常或出生缺陷的事件不作为SAE进行报告。因疾病进展的症状和体征而引起的死亡作为SAE进行报告。
本公开中所述“有效量”或“有效治疗量”包含足以改善或预防医学病症的症状或病症的量。有效量还意指足以允许或促进诊断的量。用于特定患者或兽医学受试者的有效量可依据以下因素而变化：如待治疗的病症、患者的总体健康情况、给药的方法途径和剂量以及副作用严重性。有效量可以是避免显著副作用或毒性作用的最大剂量或给药方案。
具体实施方式
以下结合实施例用于进一步描述本公开，但这些实施例并非限制本公开的范围。
实施例1、式(I)所示化合物对外周T细胞淋巴瘤的有效性研究
1.1药物：式(I)所示化合物(WO2017084494A)，规格：50mg/片、200mg/片；
1.2给药方式：350mg，一日两次，28天为一个周期。
1.3入组标准，复发或难治的T淋巴细胞淋巴瘤。
350mg组共入组24例复发难治的PTCL患者，其中16例接受过西达本胺，将所有患者按照不区分既往治疗及既往接受过西达本胺治疗进行效果数据分析，具体见表1。
表1.不同组的客观缓解率
Figure PCTCN2022115763-appb-000002
Figure PCTCN2022115763-appb-000003
24例入组的PTCL，总体ORR为50％；其中PTCL-NOS 9例，AITL15例，两组ORR分别为44.4％与53.3％。ES集18例，ORR为66.7％；其中PTCL-NOS 7例，AITL11例，两组的ORR分别为57.1％与72.7％。
24例入组的PTCL中16例接受过西达苯胺，总体ORR为56.3％；其中PTCL-NOS 6例，AITL10例，两组的ORR分别为66.7％与50.0％。ES集14例，ORR为64.3％；其中PTCL-NOS 6例，AITL8例，两组的ORR分别为66.7％与62.5％。

Claims (6)

  1. 一种式(I)所示化合物或其药学上可接受的盐在制备治疗T细胞淋巴瘤的药物中的用途，
    Figure PCTCN2022115763-appb-100001
  2. 根据权利要求1所述的用途，所述的T细胞淋巴瘤为外周T细胞淋巴瘤(成熟T和NK细胞淋巴瘤)，优选血管免疫母细胞性T细胞淋巴瘤、间变性大细胞淋巴瘤、外周T淋巴细胞瘤-非特指型或NK/T细胞淋巴瘤，最优选血管免疫母细胞性T细胞淋巴瘤或外周T淋巴细胞瘤-非特指型。
  3. 据权利要求2所述的用途，所述外周T细胞淋巴瘤为复发/难治外周T细胞淋巴瘤。
  4. 根据权利要求2所述的用途，所述的外周T细胞淋巴瘤为接受过一线化疗和/或至少一种选自组蛋白去乙酰化酶抑制剂、叶酸代谢抑制剂、或抗CD30单抗治疗的外周T细胞淋巴瘤治疗，优选地，所述的外周T细胞淋巴瘤为接受过一线化疗，或接受过一线化疗和至少一种选自组蛋白去乙酰化酶抑制剂、叶酸代谢抑制剂、或抗CD30单抗治疗的外周T细胞淋巴瘤。
  5. 根据权利要求1-4任一项所述的用途，式(I)所示化合物或其药学 上可接受的盐的给药剂量选自1mg-800mg，给药频次为一日一次或一日两次。
  6. 根据权利要求5所述的用途，式(I)所示化合物或其药学上可接受的盐的给药剂量选自50mg、75mg、100mg、125mg、150mg、175mg、200mg、225mg、250mg、275mg、300mg、350mg、375mg、400mg、425mg、450mg、475mg、500mg、525mg、550mg、575mg或600mg，给药频次一日一次或一日两次；优选地，式(I)所示化合物或其药学上可接受的盐的给药剂量选自50mg、100mg、200mg、300mg、350mg或400mg，给药频次为一日一次或一日两次；最优选地，式(I)所示化合物或其药学上可接受的盐的给药剂量选自200mg、300mg或350mg，给药频次为一日一次或一日两次。
PCT/CN2022/115763 2021-08-30 2022-08-30 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途 WO2023030299A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020247010785A KR20240056564A (ko) 2021-08-30 2022-08-30 T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도
PE2024000331A PE20240881A1 (es) 2021-08-30 2022-08-30 Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
CA3230149A CA3230149A1 (en) 2021-08-30 2022-08-30 Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
AU2022340500A AU2022340500A1 (en) 2021-08-30 2022-08-30 Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
IL311097A IL311097A (en) 2021-08-30 2022-08-30 Use of an EZH2 inhibitor in the preparation of drugs for the treatment of T-cell lymphoma
CN202280058583.6A CN117956995A (zh) 2021-08-30 2022-08-30 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途
EP22863434.1A EP4393490A1 (en) 2021-08-30 2022-08-30 Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
CONC2024/0003923A CO2024003923A2 (es) 2021-08-30 2024-03-27 Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111001663.1 2021-08-30
CN202111001663 2021-08-30

Publications (1)

Publication Number Publication Date
WO2023030299A1 true WO2023030299A1 (zh) 2023-03-09

Family

ID=85411942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/115763 WO2023030299A1 (zh) 2021-08-30 2022-08-30 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途

Country Status (10)

Country Link
EP (1) EP4393490A1 (zh)
KR (1) KR20240056564A (zh)
CN (1) CN117956995A (zh)
AU (1) AU2022340500A1 (zh)
CA (1) CA3230149A1 (zh)
CO (1) CO2024003923A2 (zh)
IL (1) IL311097A (zh)
PE (1) PE20240881A1 (zh)
TW (1) TW202327597A (zh)
WO (1) WO2023030299A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2017084494A1 (zh) 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN110179796A (zh) * 2018-02-23 2019-08-30 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2017084494A1 (zh) 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN110179796A (zh) * 2018-02-23 2019-08-30 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途

Also Published As

Publication number Publication date
TW202327597A (zh) 2023-07-16
CO2024003923A2 (es) 2024-06-27
PE20240881A1 (es) 2024-04-24
KR20240056564A (ko) 2024-04-30
CA3230149A1 (en) 2023-03-09
EP4393490A1 (en) 2024-07-03
AU2022340500A1 (en) 2024-04-11
CN117956995A (zh) 2024-04-30
IL311097A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
KR20160148050A (ko) 라퀴니모드를 이용한 크론병의 치료
US11680036B1 (en) Methods for making and using endoxifen
KR20140138694A (ko) 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
JP6933659B2 (ja) トリプルネガティブ乳癌の治療方法
JP2022516662A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
TW202214242A (zh) 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途
CN115778956A (zh) 用于治疗癌症的口服给药紫杉醇和P-gp抑制剂的治疗组合
WO2020192506A1 (zh) 西奥罗尼用于小细胞肺癌的治疗
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2023030299A1 (zh) 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途
US20210353648A1 (en) Grapiprant unit dosage forms
TW202034955A (zh) 使用免疫調節治療癌症之新穎方法
JP2022511126A (ja) Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用
US20190060330A1 (en) Application of 4-hydroxy salicylanilide in preparation of anti-myeloma or anti-lymphoma drugs
CN115551509A (zh) 包含craf抑制剂的治疗组合
WO2018133838A1 (zh) Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2024140833A1 (zh) 药物组合及其应用
WO2014172857A1 (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途
WO2022199656A1 (zh) 药物组合、包含其的试剂盒及其用途
CN115364231B (zh) 一种增强ezh2抑制剂抗肿瘤作用的药物组合物及其用途
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy
Bertolín Pipeline on the Move
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
KR20210020788A (ko) 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
WO2024022282A1 (zh) 吡啶胺化合物在特定ros1基因融合的非小细胞肺癌中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22863434

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 311097

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 18687272

Country of ref document: US

Ref document number: 2024513260

Country of ref document: JP

Ref document number: 202280058583.6

Country of ref document: CN

Ref document number: 3230149

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2401001326

Country of ref document: TH

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024003810

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202490609

Country of ref document: EA

Ref document number: 2022863434

Country of ref document: EP

Ref document number: AU2022340500

Country of ref document: AU

Ref document number: 2022340500

Country of ref document: AU

Ref document number: 809382

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20247010785

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022340500

Country of ref document: AU

Date of ref document: 20220830

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2022863434

Country of ref document: EP

Effective date: 20240328

ENP Entry into the national phase

Ref document number: 112024003810

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240227